ESR1 and neoplasm: However, CDK4/6 inhibitors, currently approved for the treatment of estrogen receptor- positive breast cancer, displayed mainly a cytostatic effect when administered alone, whereas combination therapies demonstrated an enhanced efficacy in different tumor types [26,27].